Skip to main content

CCTG Connection



Published:
Category: Publications
BLC4 primary publication: Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer.
 
Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP. SWOG S1605. European Urology 84: 536-544.
Read More

Published:
Category: Publications

CCTG will be presenting the following at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. ASH is the world's largest professional gathering of both clinicians and scientists around the world who are working to conquer blood diseases.


CCTG SC.26: Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Read More

Published:
Category: Trials
Trial closure:  MA38

Permanent trial closure of the MA38 trial: Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer.

Read More

Published:
Category: Trials

CCTG pleased to announce that the GA.4 study: A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma has been centrally activated. 

Read More



Published:
Category: Group updates
Welcome to Patient Representative Jasmine Heuring

A very warm welcome to Jasmine Heuring who has joined the CCTG Patient Representatives Committee and will be supporting the Adolescents & Young Adults and Sarcoma Disease Site Committees. Jasmine is from Winnipeg Manitoba and is a cancer advocate and healthcare analyst.

Read More

Published:
Category: News

From an article by Kevin Connor - Published Nov 12, 2023  •  Toronto Sun

It is a full circle for Katy Kosyachkova.

Read More

Published:
Category: News
CCTG NE2 (STOPNET) trial was presented at the 25th Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting

The upcoming CCTG NE2 (STOPNET) trial was presented at the 25th Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting that was held in Aotearoa New Zealand from November 13 – 16.

Read More

Published:
Category: Publications
PA6: Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial. MA20: Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Read More